Familial Mediterranean fever (fMf) is an inherited condition characterized by polyserositis and is sometimes complicated by AA renal amyloidosis leading to nephrotic syndrome and renal failure. We present a case of a man with fMf who presented with rapidly progressive renal failure caused by light chain deposition disease. This disease association has not previously been described in the medical literature.

An open, randomised, cross-over study was performed to investigate the pharmacokinetics of enalaprilat, administered as 20 mg enalapril both as monotherapy and in combination with hydrochlorothiazide (HCTZ 12.5 mg). Three groups of 6 hypertensive patients were enrolled [untreated diastolic blood pressure (DBP) 90-115 mm Hg]; normal renal function [glomerular filtration rate (GFR) > 81 ml min-1 1.73 m-2], mild renal impairment (GFR 51-80 ml min-1 1.73 m-2), and moderate renal impairment (GFR 31-50 ml min-1 1.73 m-2). The pharmacokinetics of enalaprilat and enalaprilat plus HCTZ correlated predictably with renal impairment with increased plasma concentrations and decreased urinary elimination at lower values of GFR. The coadministration of HCTZ had no significant effect on the pharmacokinetics of enalaprilat in any group. We conclude that although the pharmacokinetics of both enalaprilat and HCTZ are related to renal function, HCTZ has no significant effect on the pharmacokinetics of enalaprilat and that dosage adjustment for both regimens should be based on renal function.

Methotrexate Pneumonitis in Rheumatoid Arthritis–a Dramatic Response to Treatment Get access D. MULHERIN, D. MULHERIN *Department of Rheumatology, St Vincent's HospitalDublin, Ireland Search for other works by this author on: Oxford Academic PubMed Google Scholar J. M. CUMMISKEY, J. M. CUMMISKEY *Department of Rheumatology, St Vincent's HospitalDublin, Ireland Search for other works by this author on: Oxford Academic PubMed Google Scholar G. D. DOYLE, G. D. DOYLE †The Blackrock ClinicDublin, Ireland Search for other works by this author on: Oxford Academic PubMed Google Scholar O. FITZGERALD O. FITZGERALD *Department of Rheumatology, St Vincent's HospitalDublin, Ireland Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, Volume 31, Issue 5, May 1992, Pages 356–357, https://doi.org/10.1093/rheumatology/31.5.356 Published: 01 May 1992 Article history Accepted: 23 January 1992 Published: 01 May 1992

British Journal of UrologyVolume 70, Issue 3 p. 331-332 Leiomyoma of the Renal Pelvis A. O'BRIEN, Corresponding Author A. O'BRIEN Departments of Urology and Histopathology, Beaumont Hospital, Dublin, Ireland2Department of Urology, Craigavon Area Hospital, Craigavon, N. Ireland.Search for more papers by this authorB. SINNOTT, B. SINNOTT Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorP. McLEAN, P. McLEAN Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorG. D. DOYLE, G. D. DOYLE Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this author A. O'BRIEN, Corresponding Author A. O'BRIEN Departments of Urology and Histopathology, Beaumont Hospital, Dublin, Ireland2Department of Urology, Craigavon Area Hospital, Craigavon, N. Ireland.Search for more papers by this authorB. SINNOTT, B. SINNOTT Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorP. McLEAN, P. McLEAN Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorG. D. DOYLE, G. D. DOYLE Departments of Urology and Histopathology, Beaumont Hospital, Dublin, IrelandSearch for more papers by this author First published: September 1992 https://doi.org/10.1111/j.1464-410X.1992.tb15746.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume70, Issue3September 1992Pages 331-332 RelatedInformation

Acetyl-L-carnitine 1.5 g and 3.0 g was administered as three divided doses on each of two occasions to 24 people with varying renal failure (creatinine clearance 127 – 8 ml·min−1). Plasma and urinary concentrations of total-L-carnitine, free (non-esterified) carnitine, short-chain esters and acetyl-L-carnitine were measured.

Amlodipine was administered as 14 single 5-mg oral daily doses to 27 male subjects with renal function ranging from normal to haemodialysis-dependent. Blood specimens were obtained for measurement of plasma amlodipine concentrations for 24 h following the first dose, for 168 h following the final dose and during daily administration of amlodipine. Amlodipine was well tolerated.

Acta Psychiatrica ScandinavicaVolume 80, Issue S350 p. 89-90 The pharmacokinetics of paroxetine in renal impairment G. D. Doyle, G. D. Doyle Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorM. Laher, M. Laher Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorJ. G. Kelly, J. G. Kelly Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorM. M. Byrne, M. M. Byrne Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this authorA. Clarkson, A. Clarkson Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this authorB. D. Zussman, B. D. Zussman Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this author G. D. Doyle, G. D. Doyle Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorM. Laher, M. Laher Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorJ. G. Kelly, J. G. Kelly Beaumont Hospital, Dublin, IrelandSearch for more papers by this authorM. M. Byrne, M. M. Byrne Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this authorA. Clarkson, A. Clarkson Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this authorB. D. Zussman, B. D. Zussman Beecham Pharmaceuticals Research Division, Medicinal Research Centre, Harlow, Essex, United KingdomSearch for more papers by this author First published: June 1989 https://doi.org/10.1111/j.1600-0447.1989.tb07181.xCitations: 39AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1 Brett MA., Dierdorf H.-D., Zussman BD., Coates PE. Determination of paroxetine in human plasma, using high-performance liquid chromatography with fluorescence detection. J Chromatogr 1987: 419: 438–444. 10.1016/0378-4347(87)80313-4 CASPubMedWeb of Science®Google Scholar 2 Gibaldi M., Perrier, D. Pharmacokinetics. New York : Marcel Dekker Inc., 1975. Google Scholar Citing Literature Volume80, IssueS350June 1989Pages 89-90 ReferencesRelatedInformation

1. Lisinopril and enalapril were administered as 2.5 mg single doses and as eight single daily 2.5 mg doses to separate groups of six patients with chronic renal failure. Patients were receiving regular haemodialysis. 2. In the absence of haemodialysis, the decline in plasma concentrations of lisinopril and enalaprilat was extremely slow and plasma concentrations were generally high. 3. Haemodialysis had large effects on plasma concentrations of lisinopril and enalaprilat. A 4 h period reduced plasma concentrations of both drugs by around one-half and often by significantly more than this. Even 1 or 2 h of haemodialysis had significant effects. 4. Haemodialysis plasma clearance was similar for both drugs with mean values of the order of 40 ml min-1. Clearance did not markedly differ when measured after 1, 2 or 4 h of haemodialysis or after single or multiple doses of lisinopril or enalapril. 5. The design of dosage regimens of both lisinopril and enalapril for patients with severe renal impairment or chronic renal failure should take into consideration the use and effects of haemodialysis.

The antihypertensive efficacy and safety of lisinopril were assessed in 60 older patients with a mean age of 75 years (range, 65 to 85 years) in a 12-week open study. Mean (±SEM) blood pressure while sitting was reduced from 190106 ± 3.31.8 mm Hg at entry to 16289 ± 3.21.6 mm Hg after 12 weeks of treatment (p <0.001). There was no significant alteration in heart rate, and postural hypertension did not occur. Mean glomerular filtration rate at entry was 61.6 ± 3.4 ml/minute and was unchanged after 12 weeks of therapy at 62.2 ± 3.0 ml/minute. Fourteen patients continued to receive lisinopril for a period of one year. Blood pressure remained controlled throughout and heart rate remained unchanged. There was a significant reduction in mean arterial pressure from 128.8 ± 1.9 mm Hg to 105.1 ± 1.5 mm Hg (p <0.001). Biochemical parameters remained unaltered. There was a significant increase in renal blood flow (p <0.025) and a corresponding reduction in renovascular resistance (p <0.001) following long-term therapy with lisinopril. Thus, lisinopril was generally well-tolerated and highly effective in lowering blood pressure in older hypertensive patients, whereas at the same time renal function was not adversely changed.

The antihypertensive efficacy and safety of lisinopril, a long-acting angiotensin-converting enzyme inhibitor, were assessed in 23 patients with hypertension associated with impaired renal function (glomerular filtration rate 60 ml/min or less) in an open study of 12 weeks' duration. Lisinopril was given orally in single daily doses. The starting dose was 2.5 mg in patients with glomerular filtration rate (GFR) of less than 30 ml/min and 5 mg in all other patients. This was titrated to a maximum of 40 mg daily according to blood pressure response. A diuretic was then added if blood pressure was not controlled. Mean sitting and standing blood pressures were significantly reduced by lisinopril treatment. The median dose of lisinopril taken was 10 mg daily (range 2.5-40 mg), and only three patients required the addition of a diuretic. The mean glomerular filtration rate was unchanged during the study (38 +/- 16.4 ml/min at baseline, 41 +/- 21.0 ml/min after 12 weeks of treatment). Twenty-two patients completed the study. One patient was withdrawn because of nausea and vomiting due to reflux oesophagitis which was probably not drug related. Another patient had transient mild angioneurotic oedema and continued on lisinopril. No clinically significant haematological or biochemical changes were observed. In conclusion, lisinopril provided effective blood pressure control and was well tolerated in this group of hypertensives who are typically difficult to treat.

Sarcoidosis and IgA nephropathy diagnosed simultaneously in a 23-year-old male patient is described. This association is most unusual. The possible inter-relationship between the two conditions is discussed.

In order to correlate symptoms, osteoid volume, and aluminum deposition in bone, 46 methacrylate-embedded biopsy specimens from 26 hemodialysis patients were examined. Osteoid volume was measured using computer-assisted morphometric analysis, and aluminum was detected using the Aluminon stain. Positive staining for aluminum was present in biopsies from 21 patients. Osteoid volume did not correlate with duration of dialysis therapy or ingestion of aluminum hydroxide but displayed a logarithmic relationship with dialysate aluminum exposure. Patients with bone pain at the time of biopsy had a greater degree of hyperosteoidosis than asymptomatic subjects. Osteoid volume in patients with fractures and positive aluminum staining decreased on withdrawal from aluminum-rich dialysate. The Aluminon staining technic is a convenient method of confirming aluminum overload.

This pilot study was undertaken to examine the safety and efficacy of enalapril in the treatment of hypertension associated with impaired renal function. Forty-one patients with glomerular filtration rate (GFR) < or = 50 ml/min received enalapril for up 12 weeks. Blood pressure, renal function, biochemistry and haematology were monitored weekly for 4 weeks and then monthly. Blood pressure was effectively reduced within 4 weeks; this reduction was maintained for at least 12 weeks. Renal function remained stable and there was no significant sustained alteration in any biochemical or haematological parameter. Requirement for additional antihypertensive drugs was reduced during enalapril therapy. These data suggest that enalapril may have a useful role in the management of hypertension associated with renal impairment.

We report an incidence of IgA neph ropathy of 14.9% encountered in a total of 562 renal biopsies examined over a period of three years. Reference is made to the incidence reported in other countries. Details of light and fluorescence microscopical findings are correlated with clinical presentation and renal function in an effort to establish prognostic parameters. The results suggest that the presence of IgM deposits with extensions into capillary loops are associated with the more severe histological patterns. In contrast, the finding of classical IgA-IgG nephropathy and the occurrence of the lesion in younger patients is associated with less extensive structural damage.